54 documents found, page 1 of 6
Testes rápidos de antigénio e efetividade da vacina contra a COVID-19 nos cuida...
Gómez, Verónica; Delaunay, Charlotte Laniece; Kissling, Esther; Verdasca, Nuno; Gomes, Licínia; Guiomar, Raquel; Machado, Ausenda; Rodrigues, Ana PaulaA disponibilização dos testes rápidos de antigénio (TRAg) permitiu que o diagnóstico de infeção por SARS-CoV-2 possa ser feito antes ou durante uma consulta médica. Este conhecimento pode condicionar a procura de cuidados e por outro lado, o Médico de Família (MF) pode ter informação sobre o estado de infeção antes do recrutamento do doente para os estudos de efetividade vacinal. Estudos com desenho de caso-con...
High-Dose Quadrivalent vs Standard Dose Influenza Vaccine Effectiveness using E...
Brito, André; Soares, Patrícia; Gómez, Verónica; Rodrigues, Ana Paula; Leite, Andreia; Machado, AusendaThis study presents an updated protocol to assess the effectiveness of the high-dose quadrivalent influenza vaccine (HD-QIV) in preventing hospitalisation due to influenza-like illness among older adults in Portugal. Using routinely collected electronic health records, we will conduct a retrospective cohort study covering the 2022/23 to 2025/26 influenza seasons, including residents of long-term care facilities...
Early COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adul...
Antunes, Liliana; Mazagatos, Clara; Martínez‐Baz, Iván; Naesens, Reinout; Borg, Maria‐Louise; Petrović, Goranka; Fatukasi, Terra; Jancoriene, LigitaWe conducted a multicentre test-negative case–control study covering the period from October 2023 to January 2024 among adult patients aged ≥18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between ...
Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Va...
Maurel, Marine; Pozo, Francisco; Pérez‐Gimeno, Gloria; Buda, Silke; Sève, Noémie; Oroszi, Beatrix; Hooiveld, Mariette; Gómez, Verónica; Domegan, LisaBackground: Influenza A(H3N2) viruses dominated early in the 2022-2023 influenza season in Europe, followed by higher circulation of influenza A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated the influenza vaccine effectiveness (VE) using a multicentre test-negative study. Materials and methods: Primary care practitioners collected information and specimens from patients consulting with acut...
Vigilância epidemiológica de infeções respiratórias: um estudo-piloto da adapta...
Gómez, Verónica; Guiomar, Raquel; Machado, Ausenda; Rodrigues, Ana PaulaA investigação epidemiológica de surtos de infeções respiratórias graves é determinante para a rápida identificação de ameaças à saúde pública. As infeções respiratórias de origem animal têm sido frequentemente reportadas nos últimos anos, incluindo gripe aviária, suína e mais recentemente em felinos e gado bovino. Após um surto de Influenza A(H5N1) em gatos na Polónia, em 2023, e em aves em Portugal desde nove...
Vaccine effectiveness against influenza hospitalisation in adults during the 20...
Rose, Angela M. C.; Pozo, Francisco; Martínez‐Baz, Iván; Mazagatos, Clara; Bossuyt, Nathalie; Cauchi, John Paul; Petrović, Goranka; Loghin, Isabela I.We conducted a multicentre hospital-based test-negative case–control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: −23–36); 20% (...
Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalis...
Antunes, Liliana; Mazagatos, Clara; Martínez-Baz, Iván; Gómez, Verónica; Borg, Maria-Louise; Petrović, Goranka; Duffy, Róisín; Dufrasne, François EThe European Medicines Agency (EMA) authorised four adapted bivalent mRNA COVID-19 vaccines for use against COVID-19 in September/October 2022: Comirnaty (BNT162b2; Pfizer-BioNTech) and Spikevax (mRNA-1273; Moderna) Original/Omicron BA.1 and Original/Omicron BA.4–5 [1]. During autumn 2022, all European Union/European Economic Area (EU/EEA) countries had vaccination campaigns in place to administer a booster dos...
Efetividade das Vacinas contra COVID-19 nos Militares da Marinha Portuguesa
Machado, Ausenda; Kislaya, Irina; Gómez, Verónica; Araújo Costa, Pedro Luís; Silva, Sílvia; Gonçalves Deus, Rui; Nunes Ramos, Luís MiguelEnquadramento e objetivos: No âmbito da campanha de vacinação para controlar a pandemia da COVID-19, importou medir o efeito da vacinação contra a COVID-19, em condições reais. Os Militares da Marinha Portuguesa, devido às suas funções de defesa e apoio à população no âmbito da pandemia, foram considerados população em elevado risco de exposição, tendo sido elegíveis para vacinação a partir de dezembro de 2020....
Monitoring COVID-19 and Influenza: The Added Value of a Severe Acute Respirator...
Torres, Ana Rita; Gómez, Verónica; Kislaya, Irina; Rodrigues, Ana Paula; Tavares, Margarida Fernandes; Pereira, Ana Catarina; Pereira, DéboraBackground: Severe acute respiratory infections (SARI) surveillance is recommended to assess the severity of respiratory infections disease. In 2021, the National Institute of Health Doutor Ricardo Jorge, in collaboration with two general hospitals, implemented a SARI sentinel surveillance system based on electronic health registries. We describe its application in the 2021/2022 season and compare the evolution...
Evaluating a training programe: European Health Information Training Programme ...
Gómez, Verónica; Sousa Uva, Mafalda; Roquette, Rita; Garcia, Ana Cristina; Matias Dias, CarlosBackground: The InfAct (Information for Action) is a Joint Action of the European Commission’s 3rd Health Programme with the main goal to build an infrastructure of a health information system for a stronger European Union and to strengthen its core elements. The InfAct Joint Action was developed along 36 months and structured in 10 work packages. Portugal co-led the Work Package 6 (WP6) of this project, which ...